Soluble programmed death-1 levels are associated with disease activity and treatment response in patients with autoimmune hepatitis

Abstract

AIH patients with active disease and incomplete response to standard treatment have similarly increased sPD-1 levels. Further, AIH patients have increased ability to up-regulate PD-1 following in vitro activation. Together these data suggests an impaired PD-1 axis in AIH.